- Report
- February 2018
- 17 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- January 2023
- 167 Pages
Global
From €3460EUR$3,600USD£2,967GBP
- Report
- April 2023
- 156 Pages
Global
€4806EUR$5,000USD£4,121GBP
- Report
- April 2023
- 114 Pages
Global
€3364EUR$3,500USD£2,885GBP
- Report
- April 2023
- 109 Pages
Global
€3364EUR$3,500USD£2,885GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €481EUR$500USD£412GBP
- Report
- January 2019
- 35 Pages
Global
From €961EUR$1,000USD£824GBP
- Report
- July 2018
- 20 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- July 2018
- 18 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- July 2018
- 19 Pages
Global
From €9612EUR$10,000USD£8,242GBP
- Report
- May 2024
- 50 Pages
Global
From €2547EUR$2,650USD£2,184GBP
- Report
- December 2022
- 210 Pages
Global
From €5507EUR$5,730USD£4,723GBP
- Report
- March 2023
- 147 Pages
Global
From €5766EUR$5,999USD£4,945GBP
- Book
- December 2011
- 368 Pages
Formoterol is a long-acting beta-2 agonist (LABA) used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. Formoterol is typically used in combination with an inhaled corticosteroid (ICS) to provide long-term control of symptoms. It is also used as a rescue medication to provide quick relief from acute symptoms.
Formoterol is available in both metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). It is also available in combination with other drugs, such as budesonide and mometasone. Formoterol is generally well-tolerated, with few side effects.
Formoterol is one of the most widely used drugs in the respiratory market. It is used to treat a variety of conditions, including asthma, COPD, and bronchospasm. It is also used as a rescue medication for acute symptoms.
Some companies in the Formoterol market include GlaxoSmithKline, Merck, Novartis, and Boehringer Ingelheim. Show Less Read more
